Navigation Links
Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
Date:3/15/2013

value to the offerings by incorporating them into proprietary flavor systems for their customers," Snyder said. 

Senomyx has made progress towards implementing the direct sales strategy by proactively reacquiring rights to certain flavor ingredients to build its product portfolio.  The Company's first product will be its S9632 sucrose modifier for use in non-alcoholic and powdered beverages.  In addition, Senomyx may also decide to directly commercialize its S6821 bitter blocker and several of its savory flavor ingredients to expand the product portfolio and further support the direct sales strategy. 

"We are eager to move forward with our direct sales strategy," Snyder commented.  "The timing is especially favorable for Senomyx's marketing of S9632, a unique flavor ingredient that allows manufacturers to restore the flavor profile in their reduced-sugar products.  The growing consumer focus on health and wellness is continuing to increase the demand for foods and beverages with reduced calories.  We believe S9632 will allow Senomyx to capitalize on this demand by providing solutions for manufacturers seeking to create new offerings that meet these needs while maintaining the taste consumers enjoy.

"2013 promises to be an exciting year for Senomyx as we build on the advances made during 2012 and initiate the new direct sales strategy announced today," Snyder said.

In management news, Catherine (Katia) Tachdjian, Ph.D., has been promoted from Executive Director to Vice President, Chemistry.  Dr. Tachdjian received her Ph.D in Chemistry in 1989 from the University of Paris Sud (France), followed by a postdoctoral appointment at Texas A&M University.  Since 1993, Dr. Tachdjian has worked as a medicinal/lead optimization chemist contributing to the development of novel molecules and leading top-performing discovery teams at several biotechnology and pharmaceutical companies.

Dr. Ta
'/>"/>

SOURCE Senomyx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... , March 29, 2015  Caris ... study data in small cell cervical cancer ... Caris Molecular Intelligence®, the company,s panomic, comprehensive ... gene mutations which may explain sensitivities and ... that identification of certain biomarkers may guide ...
(Date:3/27/2015)... RI (PRWEB) March 27, 2015 Earlier ... for the promotion of hair regrowth in adult men ... classifications I-II or Norwood Hamilton classifications of IIa-V and ... an industry plagued by products that over-promise and under-deliver, ... Capillus272Pro™, renewing faith and confidence among more than 80 ...
(Date:3/27/2015)... -- Neogen Corporation (NASDAQ: NEOG ) announced today that ... in accordance with Securities and Exchange Commission rule 10b5-1. ... Corporation, is a minority owner of this entity that ... Herbert does not have control of this entity, but ... for a portion of the shares owned by that ...
(Date:3/27/2015)... , March 27, 2015 Working ... Free Hospital in London , Richmond Pharmacology ... a global Phase 3 study for an investigational RNAi therapeutic ... orphan disease affecting the nerves and heart. ... Detail Based at St Georges University of ...
Breaking Biology Technology:Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2Neogen CEO adopts 10b5-1 Trading Plan 2
... Leonhardt,s Launchpads ( www.leonhardtslaunchpads.com ), at the ... Center ( www.uncm.edu/STIC.php ), 2330 Circadian Way, Santa ... Grand Opening on Tuesday, November 9th from 3pm ... incubator for startup businesses and high-potential entrepreneurs in ...
... Inc. Prices $50 Million Public Offering ... ... lpUnit=,PRN,; --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... Davis Phinney Foundation ( http://www.davisphinneyfoundation.org ), a non-profit foundation ... help people to live well with Parkinson,s disease, today ... Exercise and Parkinson,s: Questions and Answers from the Experts ... experts in the fields of physical therapy and exercise ...
Cached Biology Technology:OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 2OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 3OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 4OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 5OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 6OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 7OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 8OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 9Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinson's Disease 2Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinson's Disease 3Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinson's Disease 4
(Date:3/10/2015)... 10, 2015 Transforming How We ... "Personalized Medicine in Human Space Flight" by ... Goodwin , Ph.D. was recently featured by Springer Science ... years. Specifically, "Personalized Medicine in Human Space ... published in 2013 and 2014 from Springer in the ...
(Date:3/5/2015)... SAO PAULO , March 5, 2015 In ... with 41 percent of companies already using these solutions and ... of 2015. Of the latter, approximately 25 percent of the ... time. While the majority of companies in the ... is anticipated that the hybrid model will command significant attention ...
(Date:3/2/2015)... March 2, 2015 Synaptics Inc. (NASDAQ: ... human interface solutions, today announced a new implementation ... to enable rapid and secure transactions and reliable ... gaming is a turnkey solution providing mouse and ... quickly integrate fingerprint ID solutions into their product ...
Breaking Biology News(10 mins):"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
... risk of acquiring HIV rises during pregnancy, according to ... by researchers at the Johns Hopkins Bloomberg School of ... even after researchers controlled for behavior and other factors ... published in the September 30, 2005, edition of The ...
... trial, a new drug that selectively blocks immune ... kidney transplant rejection as cyclosporine, the standard anti-rejection ... drug, a co-stimulatory blocker called belatacept (LEA29Y), also ... the toxic side effects associated with standard anti-rejection ...
... have tracked down the biological trigger that gives ... bone disorder that can cause blindness and deafness. ... and could lead to new treatments for osteoporosis ... team from Lawrence Livermore and Lawrence Berkeley national ...
Cached Biology News:Pregnant women at higher risk for HIV, Uganda study finds 2New type of rejection blocker protects kidneys after transplant 2New type of rejection blocker protects kidneys after transplant 3New type of rejection blocker protects kidneys after transplant 4Researchers track down cause of a disfiguring bone disorder 2Researchers track down cause of a disfiguring bone disorder 3
... NEW VSOS-4P, all Programmable and Digital Orbital Shaker. ... been redesigned to make every day use even ... memory for up to 4 different programs. Its ... your program. Furthermore, the VSOS-4P has a pulse ...
... Fixed clamp trays ... easy Magnetic drive ... rpm 25 mm amplitude ... 25 ml to 2000 ml, including ...
... System is a fluorescent microscopy-based imaging system ... cells and automatically calculates cell viability, in ... routine function, the variability associated with the ... eliminated. Using the EasyCount ViaSure Kit, up ...
... 2-3x faster than western blotting. Get results ... Direct on gel detection. Eliminates the need ... detection methods. All reagents are ready-to-use. No ... to use. Only 2 reagents required. Guarantees a ...
Biology Products: